Skip to main content
NewslettersWatchlist

Esperion Theraptc(ESPR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.8400
Day High1.9700
Open:1.9700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stock Index Futures Mixed as Bank Jitters Weigh on Sentiment, ECB Decision in Focus
Barchart
Stocks Set To Open Mixed As Investors Await Powell Testimony
Globe Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Esperion Therapeutics (ESPR) Q2 2022 Earnings Call Transcript
Globe Newswire
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
Globe Newswire
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
Globe Newswire
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Esperion Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Globe Newswire
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Globe Newswire
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
Globe Newswire
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
Motley Fool
Esperion Therapeutics (ESPR) Q1 2022 Earnings Call Transcript
Globe Newswire
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
Globe Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
Globe Newswire
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
Globe Newswire
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
Globe Newswire
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Globe Newswire
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
Globe Newswire
Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
Motley Fool
Esperion Therapeutics (ESPR) Q4 2021 Earnings Call Transcript
Globe Newswire
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Globe Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
Globe Newswire
Esperion Announces Closing of $225 Million Public Offering
Globe Newswire
Esperion Announces Pricing of $225 Million Public Offering
Globe Newswire
Esperion Announces Proposed Public Offering
Globe Newswire
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
Globe Newswire
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
Globe Newswire
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Globe Newswire
Esperion to Participate in Upcoming Virtual Investor Conference
Globe NewsWire
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol

Profile

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.